News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Study Shows Teva Pharmaceutical Industries Limited’s Laquinimod Slows MS
June 20, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, June 20 (Reuters) - Teva Pharmaceutical Industries' multiple sclerosis pill laquinimod appears to slow the disease and is well-tolerated by people with the relapsing form of the incurable condition, researchers said on Friday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
Europe
MORE ON THIS TOPIC
Immunology and inflammation
Evommune Soars as Dermatitis Treatment Rivals Dupixent in Mid-Stage Trial
February 10, 2026
·
1 min read
·
Dan Samorodnitsky
Obesity
Kailera, Hengrui Push Oral GLP-1/GIP Pill to Phase 3 After Clearing Mid-Stage China Study
February 10, 2026
·
1 min read
·
Tristan Manalac
Insights
HER2’s Digital Rebirth Is Unlocking the Full Potential of ADCs
February 10, 2026
·
3 min read
·
Jennifer Smith-Parker
Gene therapy
Liver Toxicities Force Pause on Two Dose Groups of UniQure’s Mid-Stage Fabry Study
February 9, 2026
·
1 min read
·
Tristan Manalac
